Advicenne raises 2.6 million euros to strengthen its financial capacity

Pharmaceutical company Advicenne has raised nearly €2.6 million through the issuance of nearly 1.9 million new shares at a price of €1.351 each. This transaction, announced on June 30, 2025, gives the company financial visibility through the end of the third quarter of 2026.

Following this capital increase, Bpifrance holds 23.95% of the capital and 28.05% of the voting rights of Advicenne. The funds raised will notably enable the finalization of regulatory procedures in the United States for the filing of a registration application for ADV7103 in distal renal tubular acidosis (dRTA), as well as support the commercialization of Sibnayal® in Europe.

The transaction is part of a financial restructuring strategy aimed at optimizing the company's financing and strengthening its ability to achieve its clinical development objectives.